Location: Champalimaud Centre for the Unknown, Lisbon
Employer: Champalimaud Foundation
Job Type: Full Time
Position: Postdoctoral Positions
Application Starts: 26 Jul. 2021

Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud (Champalimaud Foundation), a private, non-profit research institution, is opening a call for a Postdoctoral Researcher for Papanikolaou group.

Eligible candidates must hold a PhD or Doctorate degree and will be offered an employment contract with unknown term, within the scope of the research project entitled “ProCancer-i”; with the reference “952159” – from the call Nº H2020-SC1-FA-DTS-2019-1, funded by the European Union’s Horizon 2020 research and innovation programme.

The contract is to be entered into by and between the Champalimaud Foundation and the selected candidate in accordance with all applicable legislation, including Law-Decree 57/2016, of the 29 of August of 2016 in its current edition and the General Labour Code, as well as the internal rules and regulations of the Champalimaud Foundation, taking into account the conditions set out in the above mentioned Law-Decree for the recruitment of PhD Holders within the scope of research projects funded by public funds
Work Plan

Participate in the development of Deep Learning based models and Radiomics Signatures that will be extracted from mpMRI images from a total number of 17000 patients with prostate cancer, with a focus on statistical analysis concepts including but not limited to feature selection/reduction, ML modelling using survival analysis and other clinical outcomes.

Highlights

ProCAncer-I at the ECR 2025 in Vienna

ProCAncer-I at the ECR 2025 in Vienna

ProCAncer-I will organise a Dedicated Session on the project during the European Congress of Radiology 2025 on the 26th of February 2025, at 15.00-16.00, with the title "ProCAncer-I: an AI platform integrating multiparametric MRI and AI models" where we will present...

ProCAncer-I at the EMUC24 in Lisbon

ProCAncer-I at the EMUC24 in Lisbon

The progress of major trials, the advent of artificial intelligence (AI), and interdisciplinary best practices were discussed at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC24). The congress took place from the 7th to 10th of November 2024...

Twitter feed is not available at the moment.

Stay in touch!